In the industry’s words: US’s MITA
This article was originally published in Clinica
Executive Summary
With the Medical Device User Fee and Modernization Act (MDUFMA) high on the US medtech industry’s agenda once more, the Medical Imaging & Technology Alliance (MITA) is showing itself to be a vocal contributor to the debate. Here, the association’s executive director, David Fisher, explains how MITA is dealing with the various challenges facing the imaging and radiotherapy sectors that it represents
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.